Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students
Launched by UNIVERSITY OF WESTMINSTER · Jan 24, 2024
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
The study will investigate the effect of Levagen+® Palmitoylethanolamide (PEA) supplementation on parameters of stress, well-being and cognition at defined time points. Assessments will be made using a combination of a range of stress measures, which will include physiological and psychometric parameters.
Physiological measures will include assessments of known biomarkers of the principal stress-sensitive physiological systems, the hypothalamic-pituitary-adrenal axis, and the autonomic nervous system, while psychometric measures will include established instruments to assess general health...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males \& Females
- • 18 to 40 years of age
- • Fully enrolled full-time university students from London
- Exclusion Criteria:
- • Consumption of \>14 servings of alcohol/week
- • Any learning disability (e.g. dysphasia)
- • Any neurobiological disorders (e.g. autism)
- • Smokers Any allergies/health issues related to items being ingested
- • Any serious illnesses or those on chronic medication
- • Any pregnant or lactating women
- • Any woman who is trying to conceive
- • Any chronic gastrointestinal disorders
- • Any chronic menstrual disorders (e.g. PCOS)
- • Any subjects who have undergone menopause or undergoing the perimenopause transition
- • Any eating disorders
- • Any depression/mental disorders
- • Any obese sedentary (not physically active) individual, according to BMI values
- • Any abnormal blood pressure levels
- • Shift work
About University Of Westminster
The University of Westminster is a leading UK institution dedicated to advancing knowledge and improving health outcomes through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its diverse expertise to conduct rigorous and ethically sound studies. The institution is committed to addressing pressing health challenges, fostering a culture of scientific inquiry, and translating research findings into real-world applications. By engaging with local and global communities, the University of Westminster aims to contribute significantly to the enhancement of public health and the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Mohammed Gulrez Zariwala, PhD
Principal Investigator
University of Westminster
Sanjoy Deb, PhD
Principal Investigator
Anglia Ruskin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported